Leslie W. Chinn

1.9k total citations
36 papers, 1.3k citations indexed

About

Leslie W. Chinn is a scholar working on Oncology, Genetics and Infectious Diseases. According to data from OpenAlex, Leslie W. Chinn has authored 36 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 12 papers in Genetics and 10 papers in Infectious Diseases. Recurrent topics in Leslie W. Chinn's work include Drug Transport and Resistance Mechanisms (12 papers), Chronic Lymphocytic Leukemia Research (11 papers) and HIV/AIDS drug development and treatment (10 papers). Leslie W. Chinn is often cited by papers focused on Drug Transport and Resistance Mechanisms (12 papers), Chronic Lymphocytic Leukemia Research (11 papers) and HIV/AIDS drug development and treatment (10 papers). Leslie W. Chinn collaborates with scholars based in United States, Canada and United Kingdom. Leslie W. Chinn's co-authors include Deanna L. Kroetz, Jason M. Gow, Laura M. Hodges, Russ B. Altman, Teri E. Klein, Svetlana Markova, Fahima Mayer, Nasima Mayer, Roland J. Bainton and Nicholas S. Jones and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Medicine and Journal of Neuroscience.

In The Last Decade

Leslie W. Chinn

34 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Leslie W. Chinn United States 15 507 341 237 194 193 36 1.3k
Wei Yue United States 17 565 1.1× 308 0.9× 204 0.9× 35 0.2× 178 0.9× 29 1.2k
Bernhard Ugele Germany 20 564 1.1× 408 1.2× 488 2.1× 42 0.2× 102 0.5× 36 1.8k
A Moreau France 19 292 0.6× 289 0.8× 132 0.6× 46 0.2× 217 1.1× 55 1.5k
Yogita Ghodke‐Puranik United States 18 170 0.3× 386 1.1× 216 0.9× 86 0.4× 83 0.4× 30 1.3k
Yueming Qian United States 26 310 0.6× 744 2.2× 174 0.7× 31 0.2× 101 0.5× 59 1.7k
Theodore C. Iancu Israel 23 153 0.3× 401 1.2× 68 0.3× 181 0.9× 184 1.0× 63 1.3k
Asuka Oku Japan 14 1.5k 2.9× 1.5k 4.3× 630 2.7× 67 0.3× 163 0.8× 14 3.0k
Jyrki J. Eloranta Switzerland 30 1.1k 2.2× 1.1k 3.3× 344 1.5× 34 0.2× 262 1.4× 41 2.7k
Ping He China 18 337 0.7× 581 1.7× 56 0.2× 44 0.2× 184 1.0× 60 1.3k
Michèle Maurice France 24 598 1.2× 544 1.6× 111 0.5× 28 0.1× 194 1.0× 35 1.6k

Countries citing papers authored by Leslie W. Chinn

Since Specialization
Citations

This map shows the geographic impact of Leslie W. Chinn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leslie W. Chinn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leslie W. Chinn more than expected).

Fields of papers citing papers by Leslie W. Chinn

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leslie W. Chinn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leslie W. Chinn. The network helps show where Leslie W. Chinn may publish in the future.

Co-authorship network of co-authors of Leslie W. Chinn

This figure shows the co-authorship network connecting the top 25 collaborators of Leslie W. Chinn. A scholar is included among the top collaborators of Leslie W. Chinn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leslie W. Chinn. Leslie W. Chinn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yoshida, Kenta, et al.. (2024). Simulation‐based evaluation of personalized dosing approaches for anti‐FGFR/KLB bispecific antibody fazpilodemab. CPT Pharmacometrics & Systems Pharmacology. 13(4). 544–550. 4 indexed citations
2.
Barratt, Jonathan, Rainer Boxhammer, Brian S. Schwartz, et al.. (2024). Felzartamab Durably Reduces Disease-Relevant Biomarkers through Targeting of CD38+ Plasma Cells and Plasmablasts, the Upstream Drivers of IgAN. Journal of the American Society of Nephrology. 35(10S). 1 indexed citations
3.
Metz, Martin, Gordon Sussman, Rémi Gagnon, et al.. (2021). Fenebrutinib in H1 antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial. Nature Medicine. 27(11). 1961–1969. 94 indexed citations
4.
5.
Cohen, Stanley, Katie Tuckwell, Tamiko R. Katsumoto, et al.. (2020). Fenebrutinib Versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double‐Blind, Phase II Trial. Arthritis & Rheumatology. 72(9). 1435–1446. 85 indexed citations
6.
Isenberg, David, Richard Furie, Nicholas S. Jones, et al.. (2020). OP0233 EFFICACY, SAFETY, AND PHARMACODYNAMIC EFFECTS OF THE BRUTON'S TYROSINE KINASE INHIBITOR, FENEBRUTINIB (GDC-0853), IN MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS IN A PHASE 2 CONTROLLED STUDY. Annals of the Rheumatic Diseases. 79. 148–148. 13 indexed citations
7.
Chan, Phyllis, Jiajie Yu, Leslie W. Chinn, et al.. (2020). Population Pharmacokinetics, Efficacy Exposure-response Analysis, and Model-based Meta-analysis of Fenebrutinib in Subjects with Rheumatoid Arthritis. Pharmaceutical Research. 37(2). 25–25. 12 indexed citations
8.
Durk, Matthew R., Nicholas S. Jones, Jia Liu, et al.. (2020). Understanding the Effect of Hydroxypropyl‐β‐Cyclodextrin on Fenebrutinib Absorption in an Itraconazole–Fenebrutinib Drug–Drug Interaction Study. Clinical Pharmacology & Therapeutics. 108(6). 1224–1232. 12 indexed citations
9.
Jones, Nicholas S., Helen Winter, Tamiko R. Katsumoto, et al.. (2019). Absence of Pharmacokinetic Interactions between the Bruton’s Tyrosine Kinase Inhibitor Fenebrutinib and Methotrexate. Journal of Pharmacology and Experimental Therapeutics. 371(1). 202–207. 4 indexed citations
10.
Chinn, Leslie W., Sarah Shugarts, Ashish Patel, et al.. (2013). Measuring the overall genetic component of nevirapine pharmacokinetics and the role of selected polymorphisms. Pharmacogenetics and Genomics. 23(11). 591–596. 8 indexed citations
11.
Kelly, Libusha, Hisayo Fukushima, Rachel Karchin, et al.. (2010). Functional hot spots in human ATP‐binding cassette transporter nucleotide binding domains. Protein Science. 19(11). 2110–2121. 13 indexed citations
12.
Hodges, Laura M., Svetlana Markova, Leslie W. Chinn, et al.. (2010). Very important pharmacogene summary. Pharmacogenetics and Genomics. 21(3). 152–161. 341 indexed citations
13.
Mayer, Fahima, et al.. (2009). Evolutionary Conservation of Vertebrate Blood–Brain Barrier Chemoprotective Mechanisms inDrosophila. Journal of Neuroscience. 29(11). 3538–3550. 138 indexed citations
14.
Abla, Nada, Leslie W. Chinn, Tsutomu Nakamura, et al.. (2008). The Human Multidrug Resistance Protein 4 (MRP4, ABCC4): Functional Analysis of a Highly Polymorphic Gene. Journal of Pharmacology and Experimental Therapeutics. 325(3). 859–868. 88 indexed citations
15.
Gow, Jason M., Laura M. Hodges, Leslie W. Chinn, & Deanna L. Kroetz. (2008). Substrate-Dependent Effects of Human ABCB1 Coding Polymorphisms. Journal of Pharmacology and Experimental Therapeutics. 325(2). 435–442. 48 indexed citations
16.
Gow, Jason M., Leslie W. Chinn, & Deanna L. Kroetz. (2007). The Effects of ABCB1 3′-Untranslated Region Variants on mRNA Stability. Drug Metabolism and Disposition. 36(1). 10–15. 13 indexed citations
17.
Chinn, Leslie W. & Deanna L. Kroetz. (2007). ABCB1 Pharmacogenetics: Progress, Pitfalls, and Promise. Clinical Pharmacology & Therapeutics. 81(2). 265–269. 104 indexed citations
18.
Chinn, Leslie W., et al.. (2007). Interindividual variability in the effect of atazanavir and saquinavir on the expression of lymphocyte P-glycoprotein. Journal of Antimicrobial Chemotherapy. 60(1). 61–67. 7 indexed citations
19.
Gow, Jason M., Leslie W. Chinn, Libusha Kelly, et al.. (2006). PharmGKB Submission Update: IV. PMT Submissions of Genetic Variations in ATP-Binding Cassette Transporters to the PharmGKB Network. Pharmacological Reviews. 58(1). 1–2. 15 indexed citations
20.
Chinn, Leslie W., et al.. (2003). A nonpeptide provides insight into mechanisms that regulate Drosophila melanogaster heart contractions. Peptides. 24(10). 1599–1605. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Wei Yue Breakdown of academic impact, for papers by Bernhard Ugele Breakdown of academic impact, for papers by A Moreau Breakdown of academic impact, for papers by Yogita Ghodke‐Puranik Breakdown of academic impact, for papers by Yueming Qian Breakdown of academic impact, for papers by Theodore C. Iancu Breakdown of academic impact, for papers by Asuka Oku Breakdown of academic impact, for papers by Jyrki J. Eloranta Breakdown of academic impact, for papers by Ping He Breakdown of academic impact, for papers by Michèle Maurice
Rankless by CCL
2026